COHERUS ONCOLOGY INC

Coherus CFO’s 225k option sale shows insider confidence, ties to new $1.59 exercise price and biosimilar growth—an insight for investors and industry analysts.

Coherus Oncology’s CEO buys shares at zero cost, boosting share price and showing executive confidence in biosimilar growth.

Coherus Oncology’s January 2026 insider sales: CFO and CEO off‑load shares, but routine activity keeps the stock steady—value investors, keep watch.